Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceGeneral health

Bibhitaki (Terminalia Bellirica)

One of the three fruits in triphala, promoted for cholesterol and respiratory health. The chemistry is well described and the preclinical literature is large, but human trials of the single fruit are almost nonexistent.

Evidence last reviewed: August 2026

What the science says

  • Lipid and glucose effects Limited evidence

    A systematic and comprehensive review of Terminalia bellirica found antihyperlipidaemic and antidiabetic activity across many studies, but the evidence base is dominated by rodent and in vitro work. No adequately powered randomised trial in humans supports a cholesterol or blood-sugar claim for the fruit alone.

  • Oral health as part of triphala Moderate evidence

    A meta-analysis of randomised trials found that triphala mouthrinse reduced dental plaque and gingival inflammation about as well as chlorhexidine. This is a topical rinse of the three-fruit combination, not evidence that swallowing bibhitaki capsules does anything.

  • Rejuvenative and antioxidant claims Limited evidence

    Reviews of triphala as a rasayana describe antioxidant, anti-inflammatory and gut effects, but note that clinical validation is thin and trials are small and often poorly reported.

Dosage & safety

Studied doseTypical label doses are 500–1,000 mg/day of fruit powder or extract; as triphala, 1–3 g/day. No dose has been established in controlled human trials.
SafetyLittle human safety data. Traditionally used as a laxative, so loose stools are common at higher doses. Tannin-rich, which can reduce iron absorption and irritate the stomach. Theoretical additive effects with antidiabetic and antihypertensive drugs. Avoid in pregnancy and breastfeeding for lack of data.

Scientific references

Where to buy

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in General health